Real-world data evaluating the comparative effectiveness of Entyvio® (vedolizumab) and tumor necrosis factor-alpha (TNFα)-antagonist therapy in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD).
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2018
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- 21 Feb 2018 New trial record
- 16 Feb 2018 According to a Takeda media release, These analyses were conducted by the VICTORY (Vedolizumab Health OuTComes in InflammatORY Bowel Diseases) Consortium.
- 16 Feb 2018 According to a Takeda media release, results were presented at at the 13th Congress of the European Crohns and Colitis Organization (ECCO).